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Abstract
Purpose An update of the recommendations for the
prophylaxis of delayed emesis induced by moderately
emetogenic chemotherapy discussed during the third
Perugia Consensus Conference (June 2009) sponsored by
MASCC–ESMO was presented. The review considered
new studies published since the second consensus conference
(April 2004).
Methods An online search was used conducting PubMed
and the search terms moderately, chemotherapy, and emesis
with a restriction to papers in English.
Results Overall, nine randomized controlled studies were
included: four evaluating NK1 receptor antagonists, one
palonosetron, and four dopamine receptor antagonists.
Conclusions In patients receiving a combination of anthracy-
cline plus cyclophosphamide treated with a combination of
aprepitant, a 5-HT3 receptor antagonist and dexamethasone
to prevent acute nausea and vomiting, aprepitant is suggested
to prevent delayed emesis. In patients who do not receive
aprepitant for the prophylaxis for acute emesis and in which
palonosetron is recommended, a multiday oral dexametha-
sone is the preferred treatment for the prevention of delayed
emesis. Levels of evidence and of consensus for both
recommendations are moderate.
Keywords Moderately emetogenic chemotherapy . Delayed
emesis . Neurokinin antagonists . Serotonin antagonists .
Dopamine receptor antagonists
The risk of delayed emesis has been well studied in patients
who have received a combination of an anthracycline and
cyclophosphamide but is less clear for other agents
classified as moderately emetogenic. The major prognostic
factor of the frequency of delayed onset nausea and
vomiting is the occurrence of acute-onset emesis. Therefore,
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emphasis should be placed upon the control of emesis in the
first 24 h. There are, however, randomized clinical studies that
show the efficacy of some antiemetic drugs specifically
against delayed emesis.
Table 1 shows the current Multinational Association of
Supportive Care in Cancer (MASCC), American Society of
Clinical Oncology (ASCO), American Society of Health-
System Pharmacists (ASHP), European Society for Medical
Oncology (ESMO), and National Comprehensive Cancer
Network (NCCN) practice guidelines for prophylaxis of
delayed emesis following moderately emetogenic chemother-
apy [1–5]. The recommendations range from routine use of
aprepitant, corticosteroids, 5-hydroxytryptamine (5-HT3)
antagonists in combination to the use of these agents only
when the physician feels that the risk is high enough to
warrant prophylaxis. This diversity of recommendations
reflects the limited high quality of evidence and the lack
of a precise definition of those groups who are at
substantial risk for delayed nausea and emesis. In addition,
the ASHP guidelines were published 7–10 years prior to
any of the other guidelines and before any neurokinin 1
(NK1) receptor antagonist was commercially available.
Antiemetic studies that report results in the delayed
phase of emesis are of two types: those in which the
antiemetic therapies differ only beyond day 1 and those in
which there is a difference starting at day 1 [6]. The latter
studies are problematic to interpret when there is a
difference in the control of emesis in the acute phase
because the strongest prognostic factor for delayed emesis
is the occurrence of nausea or emesis in the acute phase.
None of the studies reviewed carried out a statistical
analysis that adjusted for the differences in antiemetic
control in the acute phase. Thus, studies in which
antiemetic efficacy differs between the randomized groups
in the acute phase can describe the frequency with which
nausea and vomiting occur in the delayed phase but cannot
distinguish an effect due to administration in the delayed
phase from an effect due to better antiemetic control in the
first 24 h.
The following is a summary of the evidence available at
the time of the Perugia International Antiemetic Consensus
Conference in 2004 with respect to delayed emesis in
moderately emetogenic chemotherapy [6]:
Corticosteroids
Two out of three randomized trials have shown that
administration of dexamethasone 4 mg bid on days 2 to 5
reduces the likelihood of delayed-onset emesis with the
third study being underpowered to detect clinically impor-
tant differences.
5-Hydroxytryptamine receptor antagonists
Four studies showed a trend for better control of delayed
vomiting in the patients who received a 5-HT3 receptor
antagonist beyond day 1, but only one showed a statistically
significant difference. Two studies of palonosetron showed
efficacy that was superior to a single intravenous administration
of dolasetron or ondansetron in both the acute and delayed
phases. The superiority in the initial 24 h could explain much of
the superiority observed in the delayed phase. Less than 5% of
patients received corticosteroids combinedwith 5-HT3 receptor
antagonists and hence did not receive what is considered to be
standard therapy. For that reason, guideline groups did not
feel that the evidence was sufficient to endorse palonosetron
Group Comment Options beyond day 1
MASCC [1] Anthracycline+
cyclophosphamide (AC)
Aprepitant or dexamethasone
Moderate other than AC Dexamethasone or a
5-HT3 antagonist
ASCO [2] Anthracycline+
cyclophosphamide (AC)
Aprepitant
Moderate other than AC Dexamethasone or a
5-HT3 antagonist
ASHP [3] All moderately emetogenic 5-HT3 antagonist plus
dexamethasone
ESMO [4] Anthracycline+
cyclophosphamide (AC)
Aprepitant or dexamethasone
Moderate other than AC Corticosteroid or a 5-HT3 antagonist
NCCN [5] All moderately emetogenic Aprepitant±dexamethasone OR
Dexamethasone OR
5-HT3 antagonist±lorazepam±H2
blocker or proton pump inhibitor
Table 1 Current Consensus
Guideline Recommendations
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as the 5-HT3 receptor antagonist of choice for preventing
delayed emesis.
Dopamine receptor antagonists
Two studies provide weak evidence that the addition of a
dopamine receptor antagonist may improve the control of
delayed-onset nausea.
Neurokinin (NK)1 receptor antagonists
No studies were reported.
Update of literature
An online search was used conducting PubMed and the
search terms moderately, chemotherapy, and emesis with a
restriction to papers in English from 2004 onward. In
addition, a search was done of the terms casopitant,
aprepitant, granisetron, ondansetron, dolasetron, tropise-
tron, or palonosetron along with emesis, restricting the
search to randomized trials. Abstracts were reviewed. Studies
were included only if the subjects received moderately
emetogenic chemotherapy as defined by MASCC. A paper
that included both high and moderate semetogenicity was
considered acceptable if there was a separate analysis of the
moderately emetogenic group. Open-label or crossover design
studies were reviewed but accepted only as supportive
evidence or hypothesis-generating evidence.
NK1 receptor antagonists
Following the 2004 Perugia Consensus Conference, four
studies have been reported in which NK1 receptor antagonists
were used in patients receiving moderately emetogenic
chemotherapy. All studies were double-blinded and three
included only subjects who received an anthracycline and
cyclophosphamide (AC)-based chemotherapy regimen for
breast cancer. The fourth study enrolled patients scheduled to
receive a single dose of at least one moderately emetogenic
chemotherapy agent. All three studies with aprepitant had the
same standard therapy and experimental antiemetic therapy.
The study with casopitant differed slightly in design in that
ondansetron was given for 3 days in both the standard and
experimental groups whereas in aprepitant studies, ondanse-
tron was continued beyond day 1 only in the standard
therapy group.
In the first study, 866 patients treated with cyclophos-
phamide±doxorubicin or epirubicin were randomized to
receive oral aprepitant 125 mg on day 1 and 80 mg on
days 2 and 3 combined with oral ondansetron 8 mg bid on
day 1 only and oral dexamethasone 12 mg before
chemotherapy or oral ondansetron 8 mg bid on days 1–3
and oral dexamethasone 20 mg before chemotherapy [7].
The complete response (definite as no emesis and no need
for rescue medication) rate from days 1–5 as well as from
day 1 was significantly superior (51% versus 42% and 76%
versus 69%, respectively) with the aprepitant combination.
Numerical (but not statistical) superiority was observed on
days 2–4 (55% versus 49%). Although there was an
absolute 17% reduction in the proportion of patients with
emesis, there was no detectable effect on nausea. The
results of this study led to the introduction of aprepitant in
the update of the MASCC antiemetics recommendations
(see Table 1).
In a much smaller study, 127 patients were randomized
to the same standard and experimental therapy as in
reference 7 [8]. There was a nonsignificant trend in favor
of aprepitant in the primary outcome of complete response
from 0–120 h (46.8% vs 41.9%) and in delayed phase
(64.4% vs 57.8%) . This study was inadequately powered
in that it was designed to have an 80% chance of detecting
a 25% difference in the complete response rate.
A third study of the same design was carried out in 848
patients who received one or more of the following
different moderately emetogenic chemotherapy agents:
oxaliplatin, carboplatin, epirubicin, idarubicin, ifosfamide,
irinotecan, daunorubicin, doxorubicin, cyclophosphamide
(<1,500 mg/m2), or cytarabine (>1 g/m2) [9]. An anthracy-
cline+cyclophosphamide regimen was administered in 48%
of patients. No vomiting (the primary endpoint) was
significantly superior with the addition of aprepitant
regardless of whether patients received AC or non-AC
regimens (76.2% vs 62.1% on days 1–5, 92.0% vs 83.7%
on day 1, and 77.9% vs 66.8% on days 2–5. This is the
only study to date that has incorporated non-AC chemo-
therapy. The lack of information about the distribution and
dose of the non-AC chemotherapy in each arm means that it
is not possible to be sure that there were no important
imbalances in the emetogenicity. It should also be noted
that the analysis according to type of chemotherapy (AC vs
non-AC) was post hoc.
A study of similar but not identical design was carried
out using the NK1 receptor antagonist, casopitant, in
patients receiving AC [10]. All patients received dexameth-
asone 8 mg iv on day 1 and oral ondansetron 8 mg twice
daily on days 1–3. Patients were randomized to a single
oral dose of casopitant (150 mg on day 1), a 3-day oral
casopitant arm (150 mgday 1+50 mgdays 2–3), a 3-day iv/
oral casopitant arm (90 mg iv on day 1 and 50 mg orally on
days 2–3), or a control arm. Complete response on days 1–5
was significantly superior with casopitant (73%, 73%, and
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74%, respectively) than with the control arm (59%). In these
patients, the complete response on day 1 was similar (88%,
89%, 86%, and 85%, respectively) while on days 2–5, it was
numerically, but not statistically, superior with casopitant
(73%, 73%, 74%, and 59%). As with the adequately powered
aprepitant study, there was a large reduction in the number of
patients with emesis but no effect upon nausea.
Summary The adequately powered studies of aprepitant
and casopitant demonstrate that when added to a 5-HT3
receptor antagonist and dexamethasone, an NK1 receptor
antagonist reduces the incidence of acute and delayed
emesis induced by anthracycline and cyclophosphamide-
based chemotherapy. At present, the evidence is insuffi-
cient to recommend routine administration of an NK1
receptor antagonist for other moderately emetogenic
chemotherapy. These studies have not addressed the issue
of whether an NK1 receptor antagonist needs to be
administered beyond day 1 in order to improve emesis in
the delayed phase. Since dexamethasone was not admin-
istered beyond 24 h, the importance of a corticosteroid in
the delayed phase when an NK1 receptor antagonist is
given is not known.
Palonosetron
Recently, the combination of palonosetron (0.75 mg iv) plus
dexamethasone (16 mg iv) has been compared with granisetron
(40 μg/kg iv) plus dexamethasone in a double-blind,
randomized study involving 1,114 cancer patients who
received cisplatin (57%) or AC/epirubicin and cyclophos-
phamide (EC) (43%) chemotherapeutic regimens [11]. All
patients received dexamethasone 8 mg iv on days 2 and 3
if treated with cisplatin and 4 mg orally if treated with AC/
EC. During the acute phase, a similar complete response
was achieved (75.3% versus 73.3%, respectively). During
the delayed phase, 56.8% of patients had a complete
response in the palonosetron group compared with 44.5%
in the granisetron group (p<0.0001). Despite some short-
comings of the study (i.e., cisplatin- and non-cisplatin-
treated patients were combined and doses of dexametha-
sone lower than those recommended for acute and delayed
emesis prophylaxis), the similar results achieved in the
first 24 h permit us to conclude that palonosetron provided
more protection from delayed emesis than a single
administration before chemotherapy of granisetron. This
study does not address the issue of whether palonosetron
is superior to other 5-HT3 receptor antagonists when an
NK1 receptor antagonist is used as recommended by
guidelines. The demonstration of superiority only in the
delayed phase raises the question of whether administra-
tion of the granisetron for more than 24 h would have
achieved equivalent results to palonosetron.
Summary This study provides strong evidence that, in
patients who receive moderately emetogenic chemotherapy,
one dose of palonosetron, administered before chemotherapy,
is more efficacious in reducing the incidence of delayed
emesis than a single dose of a 5-HT3 receptor antagonist with
a shorter half-life.
Dopamine receptor antagonists
Four studies have been published [12–15]. In one, 691
untreated patients treated with doxorubicin-containing
chemotherapy plus a 5-HT3 receptor antagonist plus
dexamethasone to prevent acute emesis were randomized
to receive oral prochlorperazine 10 mg tid on days 2 and 3,
or an oral 5-HT3 receptor antagonist (ondansetron, granise-
tron, or dolasetron), or 10 mg of prochlorperazine taken as
needed [12]. The primary endpoint was mean severity of
delayed nausea. No difference in mean severity of nausea
was observed. A major limitation of this study is that it was
not double-blind.
In the second study, 232 patients who received moderately
high to highly emetogenic chemotherapy and treated with
ondansetron plus dexamethasone to prevent acute emesis
were randomized to receive on days 2–5 15 mg of
prochlorperazine spansules twice daily, or 8 mg of ondanse-
tron tablets twice daily, or 8 mg of dexamethasone tablets
twice daily [13]. This was not a double-blind study. No
differences were observed between the three antiemetic
treatments. The absence of superiority of the dexamethasone
arm is surprising, given the results from other studies of
moderately and highly emetogenic chemotherapy. This raises
the question of whether there is true equivalence among the
treatments or if the study, due to chance, poor compliance, or
some lack of sensitivity of the methodology, simply failed to
detect a true difference in efficacy.
In the third study, an open-label crossover study, 99
pretreated and chemotherapy-naive patients receiving
different moderately emetogenic chemotherapy were
randomized to receive sublingual metopimazine (15 mg
tid) or ondansetron 8 mg bid for 5 days[14]. All patients
received 48 mg of oral methylprednisolone. Treatment
was successful (no vomiting and less than two episodes of
nausea) in preventing delayed emesis in 73.6% during
treatment with metopimazine and in 57.5%, during
ondansetron. Constipation was significantly more common
in those who received ondansetron. Unfortunately, it was not a
blind study, and no information on the results achieved on
day 1 in the two groups of patients was reported.
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In the fourth study which was double-blind, 200 untreated
and previously chemotherapy-treated patients receiving differ-
ent moderately emetogenic chemotherapy were randomized to
sublingual metopimazine 15 mg tid or sublingual ondansetron
8 mg bid for 5 days [15]. No differences were shown in
complete response (53.4% vs 49.5%) or in the incidence of
emesis (23.3% vs 30.9%, respectively). Gastrointestinal
disorders (constipation and abdominal pain) were more
frequent with ondansetron. The major limitations of this
study were that treatment for preventing acute emesis was left
to each investigator’s discretion, and that results achieved on
day 1 for the two groups of patients were not reported.
Summary The results of these studies do not modify the
previous recommendation of a weak evidence that a
dopamine receptor antagonist may improve the control of
delayed emesis.
Conclusions
Patients who receive moderately emetogenic chemotherapy
known to be associated with a significant incidence of
delayed nausea and vomiting should receive antiemetic
prophylaxis for delayed emesis.
MASCC level of confidence: high; level of consensus: high
ESMO level of evidence: I; grade of recommendation: A
In breast cancer patients receiving a combination of
anthracycline plus cyclophosphamide treated with a combina-
tion of aprepitant, a 5-HT3 receptor antagonist and dexameth-
asone to prevent acute nausea and vomiting, aprepitant
should be used to prevent delayed nausea and vomiting.
MASCC level of confidence: moderate; level of consensus:
moderate
ESMO level of evidence: II; grade of recommendation: B
In patients receiving chemotherapy of moderate emetic
risk which does not include a combination of anthracycline
plus cyclophosphamide and in which palonosetron is
recommended for the prophylaxis of acute emesis, multiday
oral dexamethasone treatment is the preferred treatment for
the prevention of delayed emesis.
MASCC level of confidence: moderate; level of consensus:
moderate
ESMO level of evidence: II; grade of recommendation: B
The optimal duration and dose of dexamethasone have
not been defined.
Further studies are required to clarify the role of more
widely available dopamine receptor antagonists such as
metoclopramide, prochlorperazine, or domperidone.
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